Nothing Special   »   [go: up one dir, main page]

RU2005104113A - Использование уреазы для угнетения роста раковых клеток - Google Patents

Использование уреазы для угнетения роста раковых клеток Download PDF

Info

Publication number
RU2005104113A
RU2005104113A RU2005104113/15A RU2005104113A RU2005104113A RU 2005104113 A RU2005104113 A RU 2005104113A RU 2005104113/15 A RU2005104113/15 A RU 2005104113/15A RU 2005104113 A RU2005104113 A RU 2005104113A RU 2005104113 A RU2005104113 A RU 2005104113A
Authority
RU
Russia
Prior art keywords
composition
urease
tumor
group
composition according
Prior art date
Application number
RU2005104113/15A
Other languages
English (en)
Other versions
RU2326691C2 (ru
Inventor
Герман ЧАО (CA)
Герман ЧАО
Вах ВОНГ (CA)
Вах Вонг
Дональд СЕГАЛ (CA)
Дональд Сегал
Джерри МАКЭЛРОЙ (CA)
Джерри МАКЭЛРОЙ
Джон ДОЧЕРТИ (CA)
Джон Дочерти
Джоди ДИКСТЕЙН (CA)
Джоди Дикстейн
Original Assignee
Хеликс Биофарма Корп. (Ca)
Хеликс Биофарма Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хеликс Биофарма Корп. (Ca), Хеликс Биофарма Корп. filed Critical Хеликс Биофарма Корп. (Ca)
Publication of RU2005104113A publication Critical patent/RU2005104113A/ru
Application granted granted Critical
Publication of RU2326691C2 publication Critical patent/RU2326691C2/ru

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (17)

1. Фармацевтическая композиция, предназначенная для использования при ингибировании роста опухолевых клеток у млекопитающего-субъекта, включающая
фермент уреазу химический фрагмент, ассоциированный с ферментом уреазой и эффективно усиливающий доставку фермента к опухолевым клеткам при введении композиции субъекту, и фармацевтический носитель.
2. Композиция по п.1, в которой указанный химический фрагмент включает гидрофильный полимер, (i) конъюгированный с ферментом уреазой, (ii) выбранный из группы, состоящей из полиэтиленгликоля, поливинилпирролидона, поливинилметилового эфира, полигидроксипропилметакриламида, полигидроксипропилметакрилата, полигидроксиэтилакрилата, полиметакриламида, полидиметилакриламида, полиметилоксазолина, полиэтилоксазолина, гидроксиэтилоксазолина, полигидроксипропилоксазолина, полиаспартамида и гидрофильных производных целлюлозы, и (iii) присутствующий в количестве, позволяющем эффективно увеличить время нахождения в кровообращении или уменьшить антигенность указанной композиции по сравнению с нативной уреазой.
3. Композиция по п.2, в которой указанный гидрофильный полимер представляет собой полиэтиленгликоль, имеющий молекулярный вес от примерно 1000 до 10000 Д.
4. Композиция по п.1 или 2, в которой указанный химический фрагмент представляет собой нацеливающий фрагмент, присоединенный к указанному ферменту уреазе, и выбранный из группы, состоящей из антитела к противоопухолевому антигену, анти-DCG антитела, и лиганда, способного специфически связываться с поверхностными рецепторами опухолевых клеток.
5. Композиция по п.4, в которой указанный нацеливающий фрагмент является полипептидом, и указанная композиция представляет собой гибридный белок, состоящий из нацеливающего фрагмента и фермента уреазы.
6. Композиция по п.4, в которой указанная уреаза включает, на своем С- или N-конце, первый спиралеобразующий пептид, характеризующийся выбранным зарядом и способностью взаимодействовать со вторым, противоположно заряженным спиралеобразующим пептидом, с образованием стабильного α-спирального биспирального гетеродимера; и указанный химический фрагмент включает нацеливающий фрагмент, содержащий указанный второй спиралеобразующий пептид.
7. Композиция по п.1, в которой указанный химический фрагмент включает везикулы, содержащие фермент уреазу в инкапсулированной форме.
8. Композиция по п.7, в которой указанные везикулы представляют собой липосомы, имеющие большое время циркуляции в крови благодаря наличию наружного покрытия из полиэтиленгликольных цепей, и размеры, позволяющие им экстравазировать в участки опухоли при внутривенном введении композиции.
9. Композиция по п.7, в которой указанные везикулы представляют собой липосомы, имеющие поверхностно-связанные нацеливающие фрагменты, выбранные из группы, состоящей из антитела к противоопухолевому антигену, анти-hCG антитела и лигандов, способных специфически связываться с поверхностными рецепторами опухолевых клеток.
10. Композиция по п.7, дополнительно включающая агент, инкапсулированный в указанных липосомах, и выбранный из группы, состоящей из мочевины, терапевтически активного противоопухолевого агента и агента визуализации.
11. Композиция по п.1, в которой указанная уреаза представляет собой растительную или бактериальную уреазу.
12. Композиция по п.1, дополнительно включающая слабоосновное противоопухолевое соединение, эффективность которого снижается в градиенте более высокого внутриклеточного/более низкого внеклеточного значений рН в солидной опухоли.
13. Композиция по п.12, в которой противоопухолевое соединение выбирают из группы, состоящей из доксорубицина, даунорубицина, митоксантрона, эпирубицина, митомицина, блеомицина, алкалоидов барвинка (Vinca), таких как винбластин и винкристин, алкилирующих агентов, таких как циклофосфамид и мехлорэтамина гидрохлорид, и противоопухолевых производных пурина и пиримидина.
14. Использование фермента уреазы в производстве лекарственного средства для лечения или диагностики опухоли у млекопитающего-субъекта, получающего лечение слабоосновным противоопухолевым соединением, эффективность которого снижается в градиенте более высокого внутриклеточного/более низкого внеклеточного значений рН в солидной опухоли.
15. Использование по п.14, в котором фермент уреаза присоединен к нацеливающему фрагменту, выбранному из группы, состоящей из антитела к противоопухолевому антигену, анти-hCG антитела и лигандов, способных специфически связываться с поверхностными рецепторами опухолевых клеток.
16. Использование по п.14, в котором указанное противоопухолевое соединение выбирают из группы, состоящей из доксорубицина, даунорубицина, митоксантрона, эпирубицина, митомицина, блеомицина, алкалоидов барвинка (Vinca), таких как винбластин и винкристин, алкилирующих агентов, таких как циклофосфамид и мехлорэтамина гидрохлорид, и противоопухолевых производных пурина и пиримидина.
17. Композиция для генной терапии, предназначенная для использования при ингибировании роста опухолевых клеток у млекопитающего-субъекта, включающая нацеливающий вектор, эффективно обеспечивающий при введении субъекту селективную трансфекцию опухолевых клеток, и переносимую в указанном векторе рекомбинантную последовательность нуклеиновой кислоты, обеспечивающую продуцирование мРНК уреазы в подвергнутых трансфекции опухолевых клетках.
RU2005104113/15A 2002-07-18 2003-07-16 Использование уреазы для ингибирования роста раковых клеток RU2326691C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39724402P 2002-07-18 2002-07-18
US60/397,244 2002-07-18

Publications (2)

Publication Number Publication Date
RU2005104113A true RU2005104113A (ru) 2005-09-10
RU2326691C2 RU2326691C2 (ru) 2008-06-20

Family

ID=30771022

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005104113/15A RU2326691C2 (ru) 2002-07-18 2003-07-16 Использование уреазы для ингибирования роста раковых клеток

Country Status (23)

Country Link
US (1) US7211250B2 (ru)
EP (2) EP2324846B1 (ru)
JP (4) JP2006501196A (ru)
KR (2) KR20050038005A (ru)
CN (1) CN100577203C (ru)
AU (1) AU2003250658B2 (ru)
BR (1) BR0312664A (ru)
CA (1) CA2492472C (ru)
DK (1) DK1530482T3 (ru)
ES (1) ES2443416T3 (ru)
HK (2) HK1158103A1 (ru)
IL (1) IL166249A (ru)
MX (1) MXPA05000778A (ru)
NO (1) NO336811B1 (ru)
NZ (1) NZ538284A (ru)
PL (1) PL217626B1 (ru)
PT (1) PT1530482E (ru)
RU (1) RU2326691C2 (ru)
SI (1) SI1530482T1 (ru)
TR (1) TR200500108T2 (ru)
UA (1) UA81634C2 (ru)
WO (1) WO2004009112A1 (ru)
ZA (1) ZA200500423B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US7769423B2 (en) * 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
WO2004023981A2 (en) * 2002-09-11 2004-03-25 Duke University Methods and compositions for blood pool identification, drug distribution quantification and drug release verification
US20070104732A1 (en) * 2003-10-24 2007-05-10 Bernard Massie Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
CA2908475C (en) * 2013-04-08 2020-09-08 Helix Biopharma Corp. Use of antibody-urease conjugates for diagnostic and therapeutic purposes
CN118873680A (zh) * 2015-01-23 2024-11-01 赫利克斯生物药品公司 用于治疗目的的抗体-脲酶缀合物
EP3515473A4 (en) 2016-09-24 2020-04-15 Helix Biopharma Corp. RESTORING THE FUNCTION OF TUMOR ACIDATED T CELLS
CA3049272A1 (en) * 2017-01-05 2018-07-12 Helix Biopharma Corporation Anti-vegfr-2 urease conjugates
JPWO2021235436A1 (ru) * 2020-05-20 2021-11-25
CA3182871A1 (en) * 2020-06-15 2021-12-23 Kortuc Inc. Sensitizer for cancer treatment
CN113433087A (zh) * 2021-06-22 2021-09-24 中南大学 一种尿素浓度快速检测方法及检测传感器和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007895B1 (fr) 1978-07-19 1983-06-22 Patrick Couvreur Nanoparticules biodégradables, compositions pharmaceutiques les contenant et procédé pour leur préparation
US4489055A (en) 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2504408B1 (fr) 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4589071A (en) 1982-04-19 1986-05-13 Nissan Motor Co., Ltd. Method and apparatus for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4824783A (en) 1983-12-20 1989-04-25 Enichem S.P.A. Oxidized sulfur derivatives of diaminophosphinyl compounds as urease inhibitors
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4837380A (en) * 1985-09-30 1989-06-06 Regents Of University Of California Liposome-calcitonin preparation
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4680333A (en) 1986-04-14 1987-07-14 National Starch And Chemical Corporation Removable hot melt pressure sensitive adhesive
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
FR2637612B1 (fr) 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
US5298399A (en) 1990-08-10 1994-03-29 Sapporo Breweries Limited Gene and process for producing a thermostable urease
US5140100A (en) 1990-12-28 1992-08-18 Cedars-Sinai Medical Center Protein that inhibits production of human choriogonadotropin
FR2683159B1 (fr) 1991-10-31 1994-02-25 Coletica Procede de fabrication de nanocapsules a paroi a base de proteines reticulees; nanocapsules ainsi obtenues et compositions cosmetiques, pharmaceutiques et alimentaires en comportant application.
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
JPH07505773A (ja) * 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
GB9300875D0 (en) 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
EP0684814B1 (en) 1993-02-22 1998-06-17 Alza Corporation Compositions for oral delivery of active agents
WO1995014093A1 (en) 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
DE69518838T2 (de) * 1994-05-18 2001-05-03 The Protein Engineering Network Of Centres Of Excellence (Pence), Inc. Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US5886143A (en) 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
JPH11511979A (ja) * 1995-09-06 1999-10-19 ババリアン・ノルディック・リサーチ・インスティテュート・アクティーゼルスカブ ヒト乳癌細胞を含むヒト乳腺細胞を標的として、連結された異種性遺伝子を発現させるためのｗａｐまたはｍｍｔｖ制御配列の使用
WO1997028179A1 (en) 1996-01-31 1997-08-07 The Regents Of The University Of California Method for inhibiting tumor cell growth
US6395712B1 (en) 1996-03-20 2002-05-28 Board Of Regents, The University Of Texas System Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
JPH1017492A (ja) * 1996-07-02 1998-01-20 Fuji Yakuhin Kogyo Kk 腫瘍細胞増殖抑制剤
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5750496A (en) * 1996-08-12 1998-05-12 Utah State University Method of controlling cryptosporidium infectons using protease inhibitors
EP0824019B1 (en) * 1996-08-13 2002-11-20 Quest International B.V. Inhibition or reduction of oral malodour
AU4907897A (en) 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
US6180114B1 (en) 1996-11-21 2001-01-30 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
GB9703633D0 (en) * 1997-02-21 1997-04-09 Imp Cancer Res Tech Cancer therapy
US6190923B1 (en) 1997-09-05 2001-02-20 David K. Johnson Diethylenetriamine-N,N′,N″-triacetic acid derivatives
FR2772025B1 (fr) 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
US6753310B1 (en) * 1998-10-16 2004-06-22 Otsuka Pharmaceutical Co., Ltd. Neovascular-specific peptides
FR2790405B1 (fr) 1999-03-02 2001-04-20 Oreal Nanocapsules a base de polymeres dendritiques
AU5646800A (en) 1999-03-02 2000-09-21 Helix Biopharma Corporation Card-based biosensor device
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
DK1189641T5 (da) * 1999-06-25 2011-04-11 Genentech Inc Humaniserede ANTI-ErbB2-antistoffer og behandling med ANTI-ErbB2-antistoffer
US6307372B1 (en) 1999-11-02 2001-10-23 Glaxo Wellcome, Inc. Methods for high throughput chemical screening using magnetic resonance imaging
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
WO2002015925A1 (fr) * 2000-08-22 2002-02-28 Kyowa Hakko Kogyo Co., Ltd. Technique de regulation de l'apoptose et polypeptide de regulation d'apoptose
US7148038B2 (en) * 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof

Also Published As

Publication number Publication date
IL166249A (en) 2011-10-31
UA81634C2 (ru) 2008-01-25
HK1076739A1 (en) 2006-01-27
SI1530482T1 (sl) 2014-03-31
JP2006501196A (ja) 2006-01-12
TR200500108T2 (tr) 2005-04-21
AU2003250658A1 (en) 2004-02-09
NO20050793L (no) 2005-04-18
CN1681528A (zh) 2005-10-12
US20040115186A1 (en) 2004-06-17
CN100577203C (zh) 2010-01-06
JP2011207913A (ja) 2011-10-20
KR20110123786A (ko) 2011-11-15
JP2016014066A (ja) 2016-01-28
CA2492472C (en) 2014-01-07
HK1158103A1 (en) 2012-07-13
KR101352826B1 (ko) 2014-01-17
CA2492472A1 (en) 2004-01-29
PL374675A1 (en) 2005-10-31
NO336811B1 (no) 2015-11-02
JP5850561B2 (ja) 2016-02-03
IL166249A0 (en) 2006-01-15
PT1530482E (pt) 2014-01-15
EP2324846B1 (en) 2014-11-12
JP2013213055A (ja) 2013-10-17
ZA200500423B (en) 2006-08-30
EP1530482A1 (en) 2005-05-18
WO2004009112A8 (en) 2005-09-15
DK1530482T3 (da) 2014-01-20
AU2003250658B2 (en) 2009-07-16
ES2443416T3 (es) 2014-02-19
WO2004009112A1 (en) 2004-01-29
NZ538284A (en) 2008-04-30
EP2324846A1 (en) 2011-05-25
US7211250B2 (en) 2007-05-01
MXPA05000778A (es) 2005-08-29
EP1530482B1 (en) 2013-10-23
PL217626B1 (pl) 2014-08-29
KR20050038005A (ko) 2005-04-25
EP1530482B9 (en) 2014-04-16
BR0312664A (pt) 2005-05-03
RU2326691C2 (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
US11701432B2 (en) Polyglutamated antifolates and uses thereof
US20230115624A1 (en) D glutamate polyglutamated antifolates and uses thereof
US20230000993A1 (en) Silicon based drug conjugates and methods of using same
RU2005104113A (ru) Использование уреазы для угнетения роста раковых клеток
Reddy et al. Folate-mediated targeting of therapeutic and imaging agents to cancers
ES2321841T3 (es) Copolimeros heterofuncionales de glicerol y polietilenglicol, sus conjugados y composiciones.
Gosselin et al. Folate receptor-targeted liposomes as vectors for therapeutic agents
AU2015240766B2 (en) Targeted polymerized nanoparticles for cancer treatment
WO2018031980A1 (en) Polyglutamated antifolates and uses thereof
JP2003528924A (ja) リガンド免疫原複合体を用いる処置方法
CN110859817A (zh) 一种纳米颗粒载药系统及其制备方法和应用
CN110804086B (zh) 一种多肽纳米载体及其制备方法和应用
AU2021204137A1 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
CN114502202A (zh) 用于通过使用基于肽核酸的试剂来治疗癌症的方法和组合物
US20050112061A1 (en) Use of a VEGF antagonist in combination with radiation therapy
EP0366770B1 (en) Liposomes coupled to hormones
Li et al. Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review
JPWO2011083845A1 (ja) 腫瘍部位に対する標的化剤
US10611796B2 (en) Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
US20110027171A1 (en) Ph sensitive liposome composition
CN115151278A (zh) 用于核酸疗法的靶向肿瘤的多肽纳米颗粒递送系统
WO2023109704A1 (zh) 一种抗体合成菌-纳米刺激剂杂合体及其抗肿瘤应用
Shin et al. A nanotherapeutic approach to selectively eliminate metastatic breast cancer cells by targeting cell surface GRP78
TW201809013A (zh) 用於藥物遞送之抗體融合蛋白
JP2003513881A5 (ru)